Introduction {#section5-1756284820927306}
============

*Helicobacter pylori* infection is associated with peptic ulcer disease and gastric cancer,^[@bibr1-1756284820927306],[@bibr2-1756284820927306]^ and population-wide eradication seems to be the most direct approach to reduce the enormous consequences of *H. pylori* infection. Implementation of *H. pylori* eradication programs requires an effective, simple, and practical antibiotic regimen. However, the efficacy of standard triple therapy containing clarithromycin, amoxicillin, and a proton-pump inhibitor (PPI) for *H. pylori* eradication has fallen below 80% due to the rising prevalence of clarithromycin resistance.^[@bibr3-1756284820927306],[@bibr4-1756284820927306]^ Several strategies have been developed to increase the efficacy of first-line *H. pylori* eradication therapies.^[@bibr3-1756284820927306],[@bibr4-1756284820927306]^ Previous studies showed that *H. pylori* produce biofilm, an extracellular polymeric matrix \[polysaccharides, deoxyribonucleic acid (DNA), proteins, and lipids\] with water channels as a strategy to overcome environmental stress and protect itself.^[@bibr5-1756284820927306],[@bibr6-1756284820927306]^ Bacteria in biofilms can be more resistant to antibiotics and human defenses than free-living ones by retarding antibiotic diffusion, allowing expression of gene resistance, presence of antibiotic-hydrolyzing enzymes, and decreasing the bacterial growth ratio.^[@bibr7-1756284820927306],[@bibr8-1756284820927306]^ Yonezawa *et al.* showed that *H. pylori* biofilm formation decreases the susceptibility to clarithromycin, and that *H. pylori* clarithromycin-resistant mutations are more frequently generated in biofilms than in planktonic cells.^[@bibr9-1756284820927306]^ *N*-acetylcysteine (NAC) has anti-biofilm activity against pathogens and was used in treating device-related infection and chronic respiratory-traction diseases.^[@bibr10-1756284820927306][@bibr11-1756284820927306]--[@bibr12-1756284820927306]^ Therefore, NAC is a promising agent to increase the efficacy of *H. pylori* eradication therapy.^[@bibr13-1756284820927306]^ Cammarota *et al.* reported that NAC was able to avoid biofilm formation and to destabilize the already-formed biofilm at concentrations of over 10 mg/ml.^[@bibr14-1756284820927306]^ Some studies have shown NAC has an additive effect on *H. pylori* eradication in first-line therapy,^[@bibr15-1756284820927306][@bibr16-1756284820927306][@bibr17-1756284820927306][@bibr18-1756284820927306]--[@bibr19-1756284820927306]^ and an Italian study suggested that NAC pretreatment before a culture-guided antibiotic regimen is effective for overcoming *H. pylori* antibiotic resistance in patients with refractory *H. pylori* infection.^[@bibr14-1756284820927306]^ However, most studies were small sized and hospital based. The antibiotic therapy used in some studies were dual therapy,^[@bibr15-1756284820927306],[@bibr19-1756284820927306]^ which were not the recommended regimens according to current guidelines.^[@bibr20-1756284820927306],[@bibr21-1756284820927306]^ Whether NAC provides adjunctive effect on standard first-line *H. pylori* treatment, including in the community populations, remains unknown. Besides, antimicrobial susceptibility was not available in previous studies and the additive effect of NAC to overcome antibiotic resistance still needs further study.

Therefore, we conducted this randomized controlled trial to assess whether adjunctive NAC may increase the efficacy of triple therapy given for 14 days in the first-line *H. pylori* eradication by recruiting both community-based and hospital-based populations.

Materials and methods {#section6-1756284820927306}
=====================

Trial design and settings {#section7-1756284820927306}
-------------------------

This multicenter, open-label, randomized trial was conducted in eight participating hospitals in Taiwan and a community population residing in an offshore island (Matsu island). The institutional review board of each participating unit approved the study. Study research staff recruited potential participants and explained the purpose and eligibility requirements of the study to them. Written informed consent was obtained from each subject before enrollment \[[ClinicalTrial.gov](http://ClinicalTrial.gov) identifier: NCT02249546\].

Patient enrollment {#section8-1756284820927306}
------------------

Symptomatic and asymptomatic adult subjects were invited to participate in our *H. pylori* screening program. Symptomatic patients who underwent esophagogastroduodenoscopy (EGD) for dyspepsia or other symptoms were eligible for enrollment if they had at least positive tests among histology, rapid urease test, culture, and serology. Asymptomatic subjects with a single positive ^13^C-urea breath test (^13^C-UBT) were also eligible for enrollment. Subjects were excluded from the study if any one of the following criteria was present: (a) history of *H. pylori* eradication; (b) history of gastrectomy; (c) gastric malignancy, including adenocarcinoma and lymphoma; (d) contraindication or previous allergic reaction to study drugs (amoxicillin, clarithromycin, NAC, or dexlansoprazole; (e) pregnancy or lactating women; (f) severe concurrent disease. Written informed consent was obtained from all patients before enrollment.

Intervention and assessment of the adverse effect {#section9-1756284820927306}
-------------------------------------------------

Eligible patients were randomized to receive either (a) NAC adjunctive triple therapy (NAC-T14) for 14 days: dexlansoprazole delayed release (DR; Dexilant^™^, Takeda Pharmaceuticals, Osaka, Japan) 60 mg once daily for 14 days, amoxicillin (amoxicillin capsules, China Chemical & Pharmaceutical Co. Ltd., Taipei, Taiwan) 1 g, clarithromycin (Klaricid^™^ XL, Abbvie SRL, Campoverde, Italy) 500 mg, NAC (Actein, Synmosa Biopharma Co., Taipei, Taiwan) 600 mg (all given twice daily) for 14 days; or (b) triple therapy alone (T14): dexlansoprazole DR 60 mg (once daily) for 14 days, amoxicillin 1 g, clarithromycin 500 mg (all given twice daily) for 14 days. The permuted block randomization sequence with a block size of 4 in a 1:1 ratio was generated by a computer. The sequence was concealed in an opaque envelope and kept by an independent research assistant in the National Taiwan University Hospital until intervention was assigned. All investigators were blind to the randomization sequence. After obtaining written informed consent from eligible subjects, the study nurses contacted the independent assistant at the National Taiwan University Hospital to obtain the next allocation number by phone to ensure adequate allocation concealment.

Outcomes {#section10-1756284820927306}
--------

The primary end-point of the study was the eradication rate. The secondary end-points were the frequency of adverse effects and compliance. All subjects were informed of the common side effects of the studied drugs before eradication therapy and were asked to record these symptoms during treatment. In the hospital setting, we arranged a standardized outpatient clinic interview at the end of treatment. The research staff assessed the adverse events and compliance using a pre-defined case report form and counted the pills not taken by the subjects. In the community setting, the adverse events and compliance were assessed by phone calls. Patients with low compliance as defined by taking less than 80% of the pills and those lost to follow up were excluded from the per protocol (PP) analysis.

Determination of eradication status, phenotypic and genotypic resistance, *CYP2C19* polymorphism {#section11-1756284820927306}
------------------------------------------------------------------------------------------------

*H. pylori* eradication was defined as a negative ^13^C-UBT at least 6 weeks after completion of treatment. The breath samples were analyzed by an infrared isotope analyzer (IRIS^®^, Wagner Analysen Technik GmbH, Bremen, Germany). A delta-over-baseline ⩾4.0 indicated positive ^13^C-UBT.

For participants who underwent EGD, gastric specimens were obtained. The specimens were cultured and maintained on CDC anaerobe agar (BD, Tokyo, Japan) containing 5% sheep blood under microaerophilic conditions (85% N~2~, 10% CO~2~, and 5% O~2~) at 37°C. Strains were identified if they were Gram negative, positive for urease, oxidase, and catalase, and had spiral or curved rods in morphology. The agar dilution method, with Mueller-Hinton agar (Remel Laboratories, Lenexa, KS), containing aged sheep blood, and incubation at 35°C for 72 h in a microaerophilic, was performed to determine the minimum inhibitory concentrations (MICs) according to the Clinical Laboratory Standards Institute protocols. The breakpoints for amoxicillin, clarithromycin, levofloxacin, tetracycline, and metronidazole resistance were defined as greater than ⩾0.5, ⩾1, \>1, \>0.5, and ⩾8 mg/l, respectively.^[@bibr22-1756284820927306],[@bibr23-1756284820927306]^ The genotypes of *gyr*A and *23S rRNA* were determined by polymerase chain reaction (PCR) followed by direct sequencing using the automatic sequencer (ABI PRISM 3100 Genetic Analyzer; Applied Biosystems, Foster city, California)^[@bibr4-1756284820927306],[@bibr23-1756284820927306]^ and *CYP2C19* polymorphism was genotyped by PCR, followed by the restriction fragment-length polymorphism method, as described previously.^[@bibr24-1756284820927306]^

Sample size estimation and statistical analysis {#section12-1756284820927306}
-----------------------------------------------

We estimated the eradication of standard triple therapy for 14 days to be 82%.^[@bibr22-1756284820927306]^ Previous trials have reported that the eradication rate in the NAC-containing group was 8--12% higher than that in the control group.^[@bibr16-1756284820927306][@bibr17-1756284820927306]--[@bibr18-1756284820927306]^ The presented trial was designed as a superiority study. To show a 9% difference in eradication rate between the triple-therapy group and NAC-triple-therapy group, a sample size of at least 340 subjects in each group was required to provide a statistical power of 90% at a 5% significance level on a two-sided test, assuming an 8% loss to follow-up rate. Participants who took at least one dose of study medication were recruited in intent-to-treat (ITT) analyses. All protocol violators, such as subjects who failed to take at least 80% of their treatment drugs, or who had unknown post-treatment *H. pylori* status, were excluded from the PP analysis. Subjects who did not return for a follow-up ^13^C-UBT were considered treatment failures.

For statistical analysis, categorical data were compared using the chi-square test or Fisher's exact test, as appropriate. Continuous data were compared using the Student's *t*-test and expressed as mean (standard deviation, SD). All *p*-values were two tailed, with the level of statistical significance specified as 0.05. The 95% confidence interval (95% CI) of the eradication rate of each regimen was calculated. Multiple logistic regression analyses were performed to detect the affecting factors of *H. pylori* eradication in both groups. The odds ratio (OR) and 95% CI were applied to measure the degree of its association. The covariates adjusted in the model included factors with an important biological impact on *H. pylori* treatment, such as age, sex, tobacco smoking (yes or no), peptic ulcer (yes or no), compliance (good compliance was defined as taking at least 80% of the drugs), *CYP2C19* polymorphism (poor metabolizer, PM, or not); *H. pylori* susceptibility or resistance to clarithromycin or amoxicillin as defined above. The statistical analyses were performed using STATA version 14.0 (StataCorp LP, College Station, TX, USA).

Results {#section13-1756284820927306}
=======

Baseline data and characteristics {#section14-1756284820927306}
---------------------------------

We enrolled 680 *H. pylori*-infected patients from 1 January 2014 to 30 June 2018. A detailed study flowchart as shown in [Figure 1](#fig1-1756284820927306){ref-type="fig"}. There were 453 patients undergoing endoscopy, and gastric biopsy was undertaken for *H. pylori* culture. We performed genotyping of *23S rRNA* in gastric biopsy specimens and it was successfully done in 332 patients. *H. pylori* were isolated in 353 patients, and antibiotic susceptibility data were available in 352 patients.

![Study flow diagram.\
ITT, intention to treat; NAC-T14, *N*-acetylcysteine with adjunctive triple therapy for 14 days; PP, per protocol; T14, triple therapy alone for 14 days.](10.1177_1756284820927306-fig1){#fig1-1756284820927306}

The baseline demographic characteristics were balanced between the two groups ([Table 1](#table1-1756284820927306){ref-type="table"}). The antimicrobial susceptibility for clarithromycin, levofloxacin, metronidazole, tetracycline, and amoxicillin was similar across two groups.

###### 

Demographic characteristics and prevalence of antibiotic resistance.

![](10.1177_1756284820927306-table1)

  -------------------------------------------------------------------------------
                                       NAC-T14\          T14\              *p*
                                       (*n* = 338)       (*n* = 338)       
  ------------------------------------ ----------------- ----------------- ------
  Male                                 49.7% (168/338)   51.8% (175/338)   0.59

  Age, mean (SD)                       50.5 (13.3)       51.0 (13.3)       0.64

  Cigarette smoking                    22.8% (77/338)    17.8% (60/338)    0.10

  Alcohol drinking                     34.0% (115/338)   30.5% (103/338)   0.32

  Peptic ulcer                         51.5% (136/264)   46.3% (117/253)   0.23

  *CYP2C19*-PM                         15.75 (36/229)    13.8% (31/225)    0.72

  BMI                                  24.6 (4.02)       24.5 (3.90)       0.68

  Obesity                              8.6% (29/338)     7.4% (25/338)     0.57

  Antimicrobial resistance                                                 

   *23S rRNA* mutation (tissue)        13.5% (23/171)    11.32 (18/159)    0.56

   *23S rRNA* mutation (strain)        16.7% (27/162)    15.2% (23/151)    0.73

   Clarithromycin resistance           18.2% (33/181)    18.9% (32/169)    0.87

   Metronidazole resistance            20.0% (36/180)    22.9% (39/170)    0.50

   Amoxicillin resistance              10.6% (19/180)    7.7% (13/170)     0.35

   Levofloxacin resistance             18.8% (34/181)    20.6% (35/170)    0.67

   Tetracycline resistance             0% (0/180)        0% (0/168)        

  *H. pylori* test positive, *n* (%)                                       

   Serology                            99.5% (210/211)   96.6% (197/204)   0.03

   Rapid urease test                   93.2% (164/176)   93.9% (168/179)   0.80

   Histology                           91.5% (172/188)   94.7% (179/189)   0.22

   Culture                             86.8% (184/212)   86.4% (171/198)   0.89

   Urea breath test                    99.3% (149/150)   100% (158/158)    0.30
  -------------------------------------------------------------------------------

BMI, body mass index; F, female; M, male; NAC-T14, *N-*acetylcysteine adjunctive triple therapy for 14 days; PM, poor metabolizer; SD, standard deviation; T14, triple therapy for 14 days.

*Helicobacter pylori* eradication rates and adverse events {#section15-1756284820927306}
----------------------------------------------------------

The eradication rates of NAC-T14 and T14 were 81.7% (276/338, 95% CI 77.5--85.8%) and 84.3% (285/338, 95% CI 80.4--88.2%) in the ITT analysis, respectively (*p* = 0.36). The PP analysis showed eradication rates in NAC-T14 group and T14 group were 85.7% (276/322, 95% CI 81.9--89.6%) and 88.0% (285/324, 95% CI 84.4--91.5%), respectively (*p* = 0.40). The adjunctive NAC therapy was not superior to standard triple therapy in both ITT and PP analyses ([Table 2](#table2-1756284820927306){ref-type="table"}). The eradication rates in clarithromycin-resistant, amoxicillin-resistant or either clarithromycin/amoxicillin resistant strains were 45.2%, 57.9%, and 52.2% respectively, for NAC-T14, and were 66.7%, 76.9%, and 70.0%, respectively, for T14 ([Table 2](#table2-1756284820927306){ref-type="table"}). For patients with antimicrobial resistance against clarithromycin and/or amoxicillin, adding NAC did not improve the eradication rates.

###### 

Eradication rates.

![](10.1177_1756284820927306-table2)

                                                          NAC-T14           T14              *p*                                
  ------------------------------------------------------- ----------------- ---------------- ----------------- ---------------- ------
  **Overall analysis**                                                                                                          
   ITT analysis                                           81.7% (276/338)   77.5--85.8%      84.3% (285/338)   80.4--88.2%      0.36
   PP analysis % (*n*/*N*)                                85.7% (276/322)   81.9--89.6%      88.0% (285/324)   84.4--91.5%      0.40
  **Eradication rates by antimicrobial susceptibility**                                                                         
   CLA-R                                                  45.2% (14/31)     27.3--64.0%      66.7% (20/30)     47.2--82.7%      0.09
   AMX-R                                                  57.9% (11/19)     15.7--84.3%      76.9% (10/13)     50.4--100.0%     0.57
   CLA-R or AMX-R                                         52.2% (24/46)     37.2--67.2%      70.0% (28/40)     55.2--84.8%      0.09
   CLA-R and AMX-R                                        25% (1/4)         −54.5% to 100%   66.7% (2/3)       −76.8% to 100%   0.35

AMX-R, amoxicillin resistant; CI, confidence interval; CLA-R, clarithromycin resistant; ITT, intention to treat; *N*, total study population number; NAC-T14, *N-*acetylcysteine adjunctive triple therapy for 14 days; PP, per-protocol; T14, triple therapy for 14 days.

The frequency of any adverse effects was similar between both groups, except for a higher proportion of bloating in T14 than in NAC-T14 (9.3% *versus* 4.6%, *p* = 0.02; [Table 3](#table3-1756284820927306){ref-type="table"}). There were marginally fewer taste-distortion (12.0% *versus* 17.2%, *p* = 0.07) and constipation (2.9% *versus* 5.9%, *p* = 0.08) events in patients treated with NAC-T14 than those treated with T14. The compliance (taking at least 80% of the drugs) was similar in patients treated with NAC-T14 or T14 (95.8% *versus* 96.2%, *p* = 0.79). Less than 5% of patients discontinued the drugs due to adverse effects in both groups.

###### 

Adverse events of eradication therapy.

![](10.1177_1756284820927306-table3)

                                              NAC-T14           T14               *p*
  ------------------------------------------- ----------------- ----------------- ------
  Any adverse effects                         37.3% (115/308)   42.8% (124/290)   0.18
  Dizziness                                   5.5% (17/308)     5.9% (17/290)     0.86
  Skin rash                                   3.6% (11/308)     2.4% (7/290)      0.41
  Headache                                    4.2% (13/308)     3.1% (9/290)      0.47
  Taste distortion                            12.0% (37/308)    17.2% (50/290)    0.07
  Abdominal pain                              6.5% (20/308)     9.7% (28/290)     0.16
  Nausea                                      3.3% (10/308)     2.4% (7/290)      0.54
  Diarrhea                                    16.9% (52/308)    18.3% (53/290)    0.66
  Constipation                                2.9% (9/308)      5.9% (17/290)     0.08
  Bloating                                    4.6% (14/308)     9.3% (17/290)     0.02
  Vomiting                                    0.7% (2/308)      1.7% (5/290)      0.22
  Discontinued drugs due to adverse effects   2.9% (9/308)      3.8% (11/290)     0.55
  Took less than 80% of drugs                 4.2% (13/308)     3.8% (11/290)     0.79
  Took the drugs correctly                    95.8% (294/308)   96.6% (281/290)   0.62

NAC-T14, *N-*acetylcysteine adjunctive triple therapy for 14 days; T14, triple therapy for 14 days.

Comparison between hospital and community settings {#section16-1756284820927306}
--------------------------------------------------

The subgroup analysis results are shown in [Table 4](#table4-1756284820927306){ref-type="table"}. In the community population, the prevalence of peptic ulcer disease and antibiotic resistance were lower. Of the reported adverse events, the compliance to treatment in the hospital population was similar to that in the community population, while subjects in the community setting had slightly higher treatment discontinuation rate and loss-to-follow-up rate. The treatment efficacies (ITTs) for *H. pylori* infection were 82.8% (82/99) and 81.9% (86/105) for NAC-T14 and T14, respectively, in the community population, and the difference was not significant.

###### 

Characteristics and outcomes according to settings.

![](10.1177_1756284820927306-table4)

                                               Hospitals         Communities                                               
  -------------------------------------------- ----------------- ----------------- ------ --------------- ---------------- ------
  Male                                         45.6% (109/239)   47.2% (110/233)   0.73   59.6% (59/99)   61.9% (65/105)   0.74
  Age, mean (SD)                               51.1 (12.7)       51.6 (12.3)       0.67   49.1 (14.6)     49.6 (15.2)      0.80
  Cigarette smoking                            21.3% (51/239)    18.0% (42/233)    0.37   26.3% (26/99)   17.1% (18/105)   
  Alcohol drinking                             30.1% (72/239)    27.0% (63/33)     0.46   43.4% (43/99)   38.1% (40/105)   0.11
  Peptic ulcer                                 39.8% (128/216)   39.3% (111/214)   0.12   16.7% (8/48)    15.4% (6/39)     0.87
  *CYP2C19*-PM                                 15.7% (36/229)    13.8% (31/225)    0.50   NA              NA               
  BMI                                          24.5 (4.0)        24.3 (3.6)        0.57   25.0 (4.0)      25.0 (4.5)       0.98
  Obesity                                      7.1% (17/239)     5.6% (13/233)     0.50   12.1 (12/99)    11.4 (12/105)    0.88
  **Resistance**                                                                                                           
   *23S rRNA* mutation (tissue)                14.2% (18/127)    12.3% (15/122)    0.66   11.4% (5/44)    8.1% (3/37)      0.63
   *23S rRNA* mutation (strain)                17.4% (23/132)    17.2% (22/128)    0.96   13.3% (4/30)    4.4% (1/23)      0.27
   Clarithromycin resistance                   19.2% (29/151)    20.3% (30/148)    0.82   13.3% (4/30)    9.1% (2/22)      0.64
   Metronidazole resistance                    22.5% (34/151)    23.1% (34/148)    0.90   6.9% (2/29)     21.8% (5/23)     0.12
   Amoxicillin resistance                      12.7% (19/150)    8.8% (13/147)     0.28   0% (0/30)       0% (0/23)        
   Levofloxacin resistance                     21.2% (32/151)    23.8% (35/147)    0.59   6.7% (2/30)     0.0% (0/23)      0.21
   Tetracycline resistance                     0% (0/151)        0% (0/146)               0% (0/29)       0% (0/22)        
  **Eradication rate**                                                                                                     
   ITT                                         81.2% (194/239)   85.4% (199/233)   0.22   82.8% (82/99)   81.9% (86/105)   0.86
   PP                                          84.7% (194/229)   89.2% (199/223)   0.15   88.2% (82/93)   85.2% (86/101)   0.54
   Any adverse events                          39.5% (94/238)    43.5% (100/230)   0.38   28.6% (20/70)   36.7% (22/60)    0.33
   Discontinued drugs due to adverse effects   2.5% (6/238)      3.0% (7/230)      0.73   4.3% (3/70)     6.7% (4/60)      0.55
   Took at least 80% drugs                     96.2% (229/238)   96.5% (222/230)   0.86   94.3% (66/70)   95.0% (57/60)    0.86
   Took the drugs correctly                    95.0% (226/238)   97.0% (223/230)   0.27   98.6% (69/70)   95.0% (57/60)    0.24
   Lost follow up                              4.2% (10/239)     4.3% (10/233)     0.95   6.1% (6/99)     3.8% (4/105)     0.46

BMI, body mass index; NAC-T14, *N-*acetylcysteine adjunctive triple therapy for 14 days; T14, triple therapy for 14 days.

Factors affecting eradication rates {#section17-1756284820927306}
-----------------------------------

[Tables 4](#table4-1756284820927306){ref-type="table"} and [5](#table5-1756284820927306){ref-type="table"} summarize the factors affecting *H. pylori* eradication rates. The eradication rates were significantly affected by clarithromycin or amoxicillin resistance in both NAC-T14 and T-14 ([Tables 2](#table2-1756284820927306){ref-type="table"} and [5](#table5-1756284820927306){ref-type="table"}). The results were consistent, using genotyping or MIC to detect clarithromycin resistance. These findings suggested that the presence of antimicrobial resistances significantly affected the eradication rates for both groups, regardless of NAC adjunctive treatment. Multiple regression analyses showed that poor compliance and antimicrobial resistance against clarithromycin were risk factors associated with NAC-T14 and T14 treatment failure ([Table 6](#table6-1756284820927306){ref-type="table"}).

###### 

Factors affecting *H. pylori* eradication rate.

![](10.1177_1756284820927306-table5)

                                                        NAC-T14                                                                     T14
  ----------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------------------------------
  **Univariate analyses**                                                                                                           
   **Clarithromycin resistance** (MIC)                                                                                              
    Resistant                                           45.2% (14/31)^[\*\*](#table-fn6-1756284820927306){ref-type="table-fn"}^     66.7% (20/30)^[\*\*](#table-fn6-1756284820927306){ref-type="table-fn"}^
    Susceptible                                         91.7% (132/144)^[\*\*](#table-fn6-1756284820927306){ref-type="table-fn"}^   96.3% (131/136)^[\*\*](#table-fn6-1756284820927306){ref-type="table-fn"}^
   ***23s rRNA* mutation** (tissue)                                                                                                 
    Yes                                                 36.4% (8/22)^[\*\*](#table-fn6-1756284820927306){ref-type="table-fn"}^      75% (12/16)^[\*](#table-fn5-1756284820927306){ref-type="table-fn"}^
    No                                                  92.4% (133/144)^[\*\*](#table-fn6-1756284820927306){ref-type="table-fn"}^   92.8% (128/138)^[\*](#table-fn5-1756284820927306){ref-type="table-fn"}^
   ***23s rRNA* mutation** (tissue)                                                                                                 
    Yes                                                 34.6% (9/26)^[\*\*](#table-fn6-1756284820927306){ref-type="table-fn"}^      66.7% (14/21)^[\*\*](#table-fn6-1756284820927306){ref-type="table-fn"}^
    No                                                  92.4% (121/131)^[\*\*](#table-fn6-1756284820927306){ref-type="table-fn"}^   94.4% (119/126)^[\*\*](#table-fn6-1756284820927306){ref-type="table-fn"}^
   **Amoxicillin resistance** (MIC)                                                                                                 
    Resistant                                           57.9% (11/19)^[\*](#table-fn5-1756284820927306){ref-type="table-fn"}^       76.9% (10/13)
    susceptible                                         86.5% (134/155)^[\*](#table-fn5-1756284820927306){ref-type="table-fn"}^     92.2% (141/153)
   **Clarithromycin or amoxicillin resistance** (MIC)                                                                               
    Resistant                                           52.2.% (24/46)^[\*\*](#table-fn6-1756284820927306){ref-type="table-fn"}^    70% (28/40)^[\*\*](#table-fn6-1756284820927306){ref-type="table-fn"}^
    Susceptible                                         94.5% (121/128)^[\*\*](#table-fn6-1756284820927306){ref-type="table-fn"}^   97.6% (122/125)^[\*\*](#table-fn6-1756284820927306){ref-type="table-fn"}^
   **Compliance (took at least 80% drugs)**                                                                                         
    Yes                                                 85.9% (249/290)                                                             89.7% (245/273)
    No                                                  83.3% (5/6)                                                                 77.8% (7/9)
   **Peptic ulcer**                                                                                                                 
    Present                                             86.5% (115/133)                                                             91.3% (105/115)
    Absent                                              81.3% (100/123)                                                             90.7% (117/129)
   **Smoking**                                                                                                                      
    Yes                                                 79.2% (57/72)                                                               84.2% (48/57)
    No                                                  87.6% (219/250)                                                             88.8% (237/267)
   ***CYP2C19* polymorphism**                                                                                                       
    PM                                                  91.8% (31/34)                                                               93.6% (29/31)
    IM/EM                                               82.9% (55/187)                                                              89.2% (165/185)
   **Settings**                                                                                                                     
    Hospital                                            84.7% (194/229)                                                             89.2% (199/223)
    Community                                           88.2% (82/93)                                                               85.2% (86/101)

*p* \< 0.05.

*p* \< 0.001.

EM, extensive metabolizer; IM, intermediate metabolizer; NAC-T14, *N-*acetylcysteine adjunctive triple therapy for 14 days; MIC, minimum inhibitory concentration; PM, poor metabolizer; T14, triple therapy for 14 days.

###### 

Multivariate analyses for factors affecting eradication rates^[\*](#table-fn8-1756284820927306){ref-type="table-fn"}^.
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  ---------------------------------------------------------------------------------
                              NAC-T14         T14                         
  --------------------------- --------------- --------- ----------------- ---------
  Clarithromycin resistance   19.6\           \<0.001   15.0\             \<0.001
                              (5.7--66.6)               (3.7--61.1)       

  Amoxicillin resistance      7.7\            0.004     3.5 (0.6--21.1)   0.18
                              (1.9--34.0)                                 

  Poor compliance             59.9\           0.02      17.4\             0.07
                              (2.6--1385.6)             (0.8--359.8)      

  Peptic ulcer                0.3\            0.06      0.7\              0.46
                              (0.09--1.0)               (0.9--3.0)        

  Smoking                     1.3\            0.31      1.7\              0.10
                              (0.8--2.1)                (0.9--3.0)        

  *CYP2C19* PM                0.7\            0.69      0.2\              0.17
                              (0.1--4.0)                (0.02\~ 2.0)      
  ---------------------------------------------------------------------------------

ORs in the multiple logistic regression models adjusted for clarithromycin resistance, amoxicillin resistance, compliance, peptic ulcer, *CYP2C19* polymorphism, age, and sex.

CI, confidence interval; NAC-T14, *N-*acetylcysteine adjunctive triple therapy for 14 days; OR, odds ratio; PM, poor metabolizer; T14, triple therapy for 14 days.

Discussion {#section18-1756284820927306}
==========

The presented study showed adjunctive treatment with NAC did not have an additive effect on the *H. pylori* eradication rate with first-line triple therapy. Our result confirmed findings of Emami *et al.*^[@bibr25-1756284820927306]^ but was against most of the earlier studies.^[@bibr15-1756284820927306][@bibr16-1756284820927306][@bibr17-1756284820927306][@bibr18-1756284820927306]--[@bibr19-1756284820927306]^ However, Zala *et al.*^[@bibr19-1756284820927306]^ and Gurbuz *et al*.^[@bibr15-1756284820927306]^ evaluated the effect of NAC on the eradication of *H. pylori* in patients receiving dual therapy, which was not recommended by current guidelines. Yoon *et al*.,^[@bibr18-1756284820927306]^ Karbasi *et al*.,^[@bibr16-1756284820927306]^ and Hamidian *et al*.^[@bibr17-1756284820927306]^ suggested that the addition of NAC to a two- or three-antibiotic regimen yielded numerically higher *H. pylori*-eradicating rate, compared with therapies without NAC. These studies were underpowered and did not reach statistical significance. Our study is the largest trial investigating the role of adjunctive treatment with NAC in standard first-line triple therapy. It provided evidence to demonstrate that NAC containing 14-day triple therapy was not superior to standard 14-day triple therapy, and the result was also supported by the recent meta-analysis.^[@bibr26-1756284820927306]^

Several reports have shown that antibiotic resistance might be the most important factor affecting the success of *H. pylori* eradication.^[@bibr4-1756284820927306],[@bibr27-1756284820927306]^ One of the hypotheses that NAC improves *H. pylori e*fficacy is to destroy bacterial biofilm and overcoming the problem of antibiotic resistance.^[@bibr28-1756284820927306]^ Nevertheless, most of the previous trials did not provide information on antibiotic resistance. The main novelty of our study included the collection of antibiotic susceptibility data from the study populations and it provides a chance to investigate whether NAC overcomes the antimicrobial resistance. Our analyses disclosed that the eradication rate for patents with clarithromycin- or amoxicillin-resistant strains in NAC-T14 was not superior to that in T14 groups (for clarithromycin: 45.2% *versus* 66.7%, respectively, *p *=* *0.09; for amoxicillin: 57.9% *versus* 76.9%, *p *=* *0.26; [Table 2](#table2-1756284820927306){ref-type="table"}) and the finding was consistent when the different methods to detect clarithromycin resistance were employed ([Table 5](#table5-1756284820927306){ref-type="table"}). The multiple regression analysis also demonstrated clarithromycin resistance was the most influential factor in the determination of treatment efficacy in both NAC-T14 and T14 groups, which suggesting NAC may not overcome antimicrobial resistance ([Table 6](#table6-1756284820927306){ref-type="table"}).

Another novel finding provided by our study is the use of Dexilant^™^ (dexlansoprazole DR) in *H. pylori* treatment. Dexlansoprazole, an R-enantiomer of lansoprazole, is a PPI with three to five times greater maximum concentration, and a longer elimination half-life than S-lansoprazole.^[@bibr29-1756284820927306]^ Dexilant^™^ employs a dual delayed-release technology designed for potent and long-lasting acid suppression. A study concluded that once-daily 60 mg dexlansoprazole was equivalent to 15.5 mg twice-daily omeprazole in Western populations, determined by the ability to maintain the median pH at 6 or higher for 24 h.^[@bibr30-1756284820927306]^ Our study, which used once-daily Dexilant^™^, demonstrated similar *H. pylori* eradication rates, compared with the studies employing widely-used twice-daily lansoprazole triple therapy (ITT: 82.4% *versus* 82.3--85.7%, PP: 86.2% *versus* 87.1-- 91%),^[@bibr4-1756284820927306],[@bibr22-1756284820927306],[@bibr31-1756284820927306]^ and the efficacy was not significantly affected by *CYP2C19* polymorphism ([Tables 5](#table5-1756284820927306){ref-type="table"}, [6](#table6-1756284820927306){ref-type="table"}). In addition to potent acid suppression of dexlansoprazole, the improved effectiveness of dexlansoprazole-based anti-*H. pylori* therapy may reflect more corpus gastritis and smaller parietal-cell masses in Asian populations. Our study suggests anti-*H. pylori* therapy with once-daily Dexilant^™^ would be a more convenient option for Asians in the real word.

The strength of this study included its large sample size, the analysis of eradication rate according to antibiotic susceptibility, the evaluation of host *CYP2C19* polymorphism, and the consideration of different enrollment settings. Treatment of asymptomatic carriers in primary care settings may make them more vulnerable to the side effects, which are highly associated with the length and complexity of the antimicrobial regimen.^[@bibr32-1756284820927306],[@bibr33-1756284820927306]^ Few reports addressed the efficacy of antibiotic treatment for *H. pylori* infection in primary care settings. Our findings support our previous trial and a study from investigators in Latin America that 14-day triple therapy is an acceptable empiric therapy with good treatment adherence for *H. pylori* infection in community populations.^[@bibr4-1756284820927306],[@bibr34-1756284820927306]^

Our study had several limitations. First, the *H. pylori* eradication rate between the two study groups was quite similar in both ITT and PP analyses (NAC-T14 *versus* T14: ITT, 81.7% *versus* 84.3%; PP, 85.7% *versus* 88%). However, it would be very difficult to recruit more than 2000 subjects in both arms to see such a narrowed difference. Our study is still the largest trial investigating the role of NAC in *H. pylori* eradication and we believe our data have contributed to *H. pylori* studies. Second, not all the participants had an endoscopy for *H. pylori* culture, and the results of antibiotic susceptibility tests were only available in approximately 51% of patients in the present study. This percentage was mainly related to the enrollment settings, and the technical difficulty of culture and MIC testing. However, this limitation did not affect the main purpose of our study (NAC-T14 *versus* T14). The treatment efficacies were indeed similar between the groups with and without antibiotic resistance data and selection bias was unlikely. Third, the reason why NAC adjunctive therapy did not show the promising efficacy in treating antibiotic-resistant *H. pylori* as shown in the previous study is unknown. One possible explanation is that Cammarota *et al.*^[@bibr14-1756284820927306]^ gave NAC pretreatment for 1 week before salvage antibiotic therapy for refractor*y H. pylori* infection, while antibiotics were given concurrently with NAC in our study. However, routine application of pretreatment with NAC in the first-line *H. pylori* treatment would raise the concern of poor compliance due to its complexity.

In conclusion, empirical dexlansoprazole DR-based triple therapy for 14 days is well tolerated and effective for *H. pylori* eradication, compared with triple therapy using twice-daily PPI. Adding a biofilm destabilizing agent, NAC, in dexlansoprazole DR-based triple therapy is not superior to the standard dexlansoprazole DR-based triple therapy in treating *H. pylori*, and is not necessary for the first-line treatment of *H. pylori* infection.
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